0001235912
false
0001235912
2023-07-25
2023-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 25, 2023
CVRx,
Inc.
(Exact name of registrant as specified in its
charter)
Delaware |
|
001-40545 |
|
41-1983744 |
(State
or other jurisdiction of
incorporation) |
|
(Commission
File Number) |
|
(I.R.S.
Employer
Identification No.) |
9201
West Broadway Avenue, Suite 650
Minneapolis,
MN 55445
(Address of principal executive offices) (Zip
Code)
(763)
416-2840
(Registrant’s telephone number, including
area code)
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange
on which registered |
Common
stock, par value $0.01 per share |
|
CVRX |
|
The Nasdaq
Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02. Results of Operations and Financial Condition.
On July 25, 2023, CVRx, Inc. issued
a press release announcing its financial results for the quarter ended June 30, 2023. A copy of the press release is attached as
Exhibit 99.1 and is incorporated herein by reference.
The information contained in this Item 2.02,
including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject
to the liabilities of that section and is not incorporated by reference into any filing under the Securities Act of 1933, as amended,
or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
CVRx, Inc. |
|
|
Date: July 25, 2023 |
By: |
/s/ Jared Oasheim |
|
|
Name: Jared Oasheim |
|
|
Its: Chief Financial Officer |
Exhibit 99.1
CVRx Reports Second Quarter 2023 Financial and
Operating Results
MINNEAPOLIS, July 25, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc.
(NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing
innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for
the second quarter of 2023.
Recent Highlights
| · | Total revenue for the second quarter of 2023 was $9.5 million, an increase of 89% over prior year quarter |
| · | U.S. Heart Failure (HF) revenue for the second quarter of 2023 was $8.3 million compared to $3.8 in the prior year
quarter, an increase of 119% over the prior year quarter |
| · | Active implanting centers in the U.S. grew to 140, an increase of 97% since June 30, 2022 |
| · | A PMA supplement was filed with the FDA for Barostim indication expansion in June 2023, in line with BeAT-HF executive steering
committee's recommendation |
"We are pleased to report another impressive quarter. Our success
continues to be driven by our U.S. heart failure business, which saw revenue growth of nearly 120% compared to the prior year quarter.
We are proud of our performance, which reflects the continued execution of our commercial strategy and the demand for Barostim in the
market,” said Nadim Yared, President and Chief Executive Officer of CVRx. “As we move forward, we remain determined to sustain
this positive momentum throughout the year. We extend our gratitude to our exceptional team for their relentless dedication to our mission
of giving each patient a fuller life.”
Second Quarter 2023 Financial and Operating Results
Revenue was $9.5 million for the three months ended June 30, 2023,
an increase of $4.5 million, or 89%, over the three months ended June 30, 2022.
Revenue generated in the U.S. was $8.3 million for the three months
ended June 30, 2023, an increase of $4.4 million, or 111%, over the three months ended June 30, 2022. HF revenue units in the
U.S. totaled 265 and 128 for the three months ended June 30, 2023 and 2022, respectively. HF revenue in the U.S. totaled $8.3 million
and $3.8 million for the three months ended June 30, 2023 and 2022, respectively. The increases were primarily driven by continued
growth in the U.S. HF business as a result of the expansion into new sales territories, new accounts and increased physician and patient
awareness of Barostim.
As of June 30, 2023, the Company had a total of 140 active implanting
centers, as compared to 122 as of March 31, 2023. Active implanting centers are customers that have completed at least one commercial
HF implant in the last 12 months. The number of sales territories in the U.S. increased by three to a total of 32 during the three months
ended June 30, 2023.
Revenue
generated in Europe was $1.2 million for the three months ended June 30, 2023, an increase of $0.1 million, or 10%, over the three
months ended June 30, 2022. Total revenue units in Europe increased to 56 for the three months ended June 30, 2023 from 52 in
the prior year period. The number of sales territories in Europe remained consistent at six for the three months ended June 30,
2023.
Gross profit was $8.0 million for the three months ended June 30,
2023, an increase of $4.2 million, or 108%, over the three months ended June 30, 2022. Gross margin increased to 84% for the three
months ended June 30, 2023 compared to 76% for the three months ended June 30, 2022. This increase was due primarily to a decrease
in the cost per unit driven by an increase in the production volume.
R&D
expenses increased $0.9 million, or 39%, to $3.3 million for the three months ended June 30, 2023 compared to the three months ended
June 30, 2022. This change was driven by a $0.6 million increase in compensation expenses as a result of increased headcount,
a $0.1 million increase in non-cash stock-based compensation expense and a $0.1 million increase in consulting fees.
SG&A
expenses increased $4.0 million, or 32%, to $16.5 million for the three months ended June 30, 2023 compared to the three months ended
June 30, 2022. This change was primarily driven by a $2.5 million increase in compensation expenses, mainly as a result of
increased headcount, a $0.8 million increase in marketing and advertising expenses associated with the commercialization of Barostim in
the U.S., a $0.4 million increase in travel expenses, and a $0.3 million increase in non-cash stock-based compensation expense.
Interest expense increased $0.5 million for the three months ended
June 30, 2023 compared to the three months ended June 30, 2022. This increase was driven by the interest expense on borrowings
under the loan agreement entered into on October 31, 2022.
Other
income, net was $0.6 million for the three months ended June 30, 2023 compared to other expense, net of $34,000 for the three months
ended June 30, 2022. The income in the second quarter of 2023 was primarily driven by interest income on interest-bearing
accounts.
Net loss was $11.7 million, or $0.56 per share, for the three months
ended June 30, 2023, compared to a net loss of $11.1 million, or $0.54 per share, for the three months ended June 30, 2022.
Net loss per share was based on 20,711,850 weighted average shares outstanding for three months ended June 30, 2023 and 20,505,228
weighted average shares outstanding for the three months ended June 30, 2022.
As of June 30, 2023, cash and cash equivalents were $90.8 million.
Net cash used in operating and investing activities was $12.95 million for the quarter ended June 30, 2023, which included our annual
premium for our directors and officers insurance of approximately $2 million. This is compared to net cash used in operating and investing
activities of $10.5 million for the three months ended March 31, 2023.
Business Outlook
For the full year of 2023, the Company now expects:
| · | Total revenue between $37.0 million and $38.5 million; up from previously issued guidance of $35.5 million and $38.0 million |
| · | Gross margin between 83.0% and 84.0%; up from previously issued guidance of 80.0% and 83.0%; |
| · | Operating expenses between $78.0 million and $80.0 million; up from previously issued guidance of $76.0 million and $80.0 million. |
For the third quarter of 2023, the Company expects to report total
revenue between $9.5 million and $10.2 million.
Webcast and Conference Call Information
The Company will host a conference call to review its results at 5:30
p.m. Eastern Time today. A live webcast of the investor conference call will be available online at the investor relations page of
the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers,
or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
About CVRx, Inc.
CVRx
is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions
for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to
improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors
located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce
the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure
patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn
more about Barostim, visit www.cvrx.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking
statements, including statements regarding our future financial performance (including our financial guidance regarding full year and
third quarter 2023 results), our anticipated growth strategies, anticipated trends in our industry, our business prospects and our opportunities.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “outlook,” “guidance,”
“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms or other similar expressions,
although not all forward-looking statements contain these words.
The forward-looking statements in this press release are only predictions
and are based largely on our current expectations and projections about future events and financial trends that we believe may affect
our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, but not limited to, our history
of significant losses, which we expect to continue; our limited history operating as a commercial company and our dependence on a single
product, Barostim; our ability to establish and maintain sales and marketing capabilities; our ability to demonstrate to physicians and
patients the merits of our Barostim; any failure by third-party payors to provide adequate coverage and reimbursement for the use of Barostim;
our competitors’ success in developing and marketing products that are safer, more effective, less costly, easier to use or otherwise
more attractive than Barostim; any failure to receive access to hospitals; our dependence upon third-party manufacturers and suppliers,
and in some cases a limited number of suppliers; a pandemic, epidemic or outbreak of an infectious disease in the U.S. or worldwide, including
the outbreak of the novel strain of coronavirus, COVID-19; any failure of clinical studies for future indications to produce results necessary
to support regulatory clearance or approval in the U.S. or elsewhere; product liability claims; future lawsuits to protect or enforce
our intellectual property, which could be expensive, time consuming and ultimately unsuccessful; any failure to retain our key executives
or recruit and hire new employees; and other important factors that could cause actual results, performance or achievements to differ
materially from those that are found in “Part I, Item 1A. Risk Factors” in our Annual Report on Form 10-K for
the year ended December 31, 2022, as such factors may be updated from time to time in our other filings with the Securities and Exchange
Commission. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained
herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
402-499-8203
laura.oneill@finnpartners.com
CVRx, INC.
Condensed Consolidated Balance Sheets
(In thousands, except share and per share data)
(Unaudited)
| |
June 30, | | |
December 31, | |
| |
2023 | | |
2022 | |
Assets | |
| | | |
| | |
Current assets: | |
| | | |
| | |
Cash and cash equivalents | |
$ | 90,815 | | |
$ | 106,194 | |
Accounts receivable, net of allowances of $602 and $679, respectively | |
| 6,726 | | |
| 5,504 | |
Inventory | |
| 10,928 | | |
| 6,957 | |
Prepaid expenses and other current assets | |
| 3,543 | | |
| 4,223 | |
Total current assets | |
| 112,012 | | |
| 122,878 | |
Property and equipment, net | |
| 1,821 | | |
| 1,698 | |
Operating lease right-of-use asset | |
| 1,113 | | |
| 334 | |
Other non-current assets | |
| 27 | | |
| 27 | |
Total assets | |
$ | 114,973 | | |
$ | 124,937 | |
Liabilities and Stockholders’ Equity | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 2,933 | | |
$ | 1,719 | |
Accrued expenses | |
| 5,992 | | |
| 6,369 | |
Total current liabilities | |
| 8,925 | | |
| 8,088 | |
Long-term debt | |
| 14,253 | | |
| 6,747 | |
Operating lease liability, non-current portion | |
| 946 | | |
| 117 | |
Other long-term liabilities | |
| 885 | | |
| 805 | |
Total liabilities | |
| 25,009 | | |
| 15,757 | |
Commitments and contingencies | |
| | | |
| | |
Stockholders’ equity: | |
| | | |
| | |
Common stock, $0.01 par value, 200,000,000 authorized as of June 30, 2023 and December 31, 2022; 20,750,910 and 20,663,736 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | |
| 208 | | |
| 207 | |
Additional paid-in capital | |
| 549,150 | | |
| 545,362 | |
Accumulated deficit | |
| (459,207 | ) | |
| (436,182 | ) |
Accumulated other comprehensive loss | |
| (187 | ) | |
| (207 | ) |
Total stockholders’ equity | |
| 89,964 | | |
| 109,180 | |
Total liabilities and stockholders’ equity | |
$ | 114,973 | | |
$ | 124,937 | |
CVRx, INC.
Condensed Consolidated Statements of Operations
and Comprehensive Loss
(In thousands, except share and per share data)
(Unaudited)
| |
Three months ended | | |
Six months ended | |
| |
June 30, | | |
June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
Revenue | |
$ | 9,500 | | |
$ | 5,031 | | |
$ | 17,479 | | |
$ | 9,107 | |
Cost of goods sold | |
| 1,517 | | |
| 1,201 | | |
| 2,845 | | |
| 2,150 | |
Gross profit | |
| 7,983 | | |
| 3,830 | | |
| 14,634 | | |
| 6,957 | |
Operating expenses: | |
| | | |
| | | |
| | | |
| | |
Research and development | |
| 3,280 | | |
| 2,355 | | |
| 6,696 | | |
| 4,613 | |
Selling, general and administrative | |
| 16,455 | | |
| 12,489 | | |
| 31,852 | | |
| 23,266 | |
Total operating expenses | |
| 19,735 | | |
| 14,844 | | |
| 38,548 | | |
| 27,879 | |
Loss from operations | |
| (11,752 | ) | |
| (11,014 | ) | |
| (23,914 | ) | |
| (20,922 | ) |
Interest expense | |
| (481 | ) | |
| — | | |
| (721 | ) | |
| — | |
Other income (expense), net | |
| 616 | | |
| (34 | ) | |
| 1,678 | | |
| (91 | ) |
Loss before income taxes | |
| (11,617 | ) | |
| (11,048 | ) | |
| (22,957 | ) | |
| (21,013 | ) |
Provision for income taxes | |
| (34 | ) | |
| (23 | ) | |
| (68 | ) | |
| (49 | ) |
Net loss | |
| (11,651 | ) | |
| (11,071 | ) | |
| (23,025 | ) | |
| (21,062 | ) |
Cumulative translation adjustment | |
| 17 | | |
| (7 | ) | |
| 20 | | |
| (13 | ) |
Comprehensive loss | |
$ | (11,634 | ) | |
$ | (11,078 | ) | |
$ | (23,005 | ) | |
$ | (21,075 | ) |
Net loss per share, basic and diluted | |
$ | (0.56 | ) | |
$ | (0.54 | ) | |
$ | (1.11 | ) | |
$ | (1.03 | ) |
Weighted-average common shares used to compute net loss per share, basic and diluted | |
| 20,711,850 | | |
| 20,505,228 | | |
| 20,702,589 | | |
| 20,479,427 | |
v3.23.2
Cover
|
Jul. 25, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 25, 2023
|
Entity File Number |
001-40545
|
Entity Registrant Name |
CVRx,
Inc.
|
Entity Central Index Key |
0001235912
|
Entity Tax Identification Number |
41-1983744
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
9201
West Broadway Avenue
|
Entity Address, Address Line Two |
Suite 650
|
Entity Address, City or Town |
Minneapolis
|
Entity Address, State or Province |
MN
|
Entity Address, Postal Zip Code |
55445
|
City Area Code |
763
|
Local Phone Number |
416-2840
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
stock, par value $0.01 per share
|
Trading Symbol |
CVRX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
CVRx (NASDAQ:CVRX)
Historical Stock Chart
From Apr 2024 to May 2024
CVRx (NASDAQ:CVRX)
Historical Stock Chart
From May 2023 to May 2024